Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Supriya Jain
Institution:
Banner MD Anderson Cancer Center at Banner North Colorado Medical Center
Observed institutions:
National University Cancer Institute, Singapore,
National University Health System,
Banner MD Anderson Cancer Center at Banner North Colorado Medical Center,
Cancer Science Institute of Singapore
ORCID:
0000-0003-3816-2032
Observed ORCID:
0000-0003-3816-2032
OpenAlex ID:
A5085101772
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2022
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
·
Clinical Cancer Research
·
15
PDF
Data from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
·
1
Data from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
·
1
Financial Toxicity of Shorter Versus Longer Partial Breast Irradiation: A Randomized Clinical Trial
2026
·
Grace L. Smith
, Chi-Fang Wu
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Supplementary Data from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Supplementary Table from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Supplementary Table from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Supplementary Figure from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Supplementary Figure from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Supplementary Figure from Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
2023
·
Joline S.J. Lim
, Andrea L.A. Wong
, et al.
Show more works
View as search
Works count:
10
Citation count:
17
H-index:
1
I10-index:
1
Year
Topic
Type